We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+7.89%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$154M
AUM Growth
-$1.62M
Cap. Flow
+$2.97M
Cap. Flow %
1.93%
Top 10 Hldgs %
69.15%
Holding
39
New
4
Increased
2
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
ELTX icon
Elicio Therapeutics
ELTX
+$4.89M
2
SAND
Sandstorm Gold
SAND
+$4.37M
3
NUVB icon
Nuvation Bio
NUVB
+$2.33M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.69M
5
APLT
Applied Therapeutics
APLT
+$1.18M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$11.5M
2
SILV
SilverCrest Metals Inc. Common Shares
SILV
+$546K
3
GRAL
GRAIL Inc
GRAL
+$1.78K
4
IRD
Opus Genetics
IRD
+$53

Sector Composition

Rank Sector Weight
1 Healthcare 62.32%
2 Materials 25.02%
3 Industrials 1.61%
4 Consumer Staples 1.49%
5 Financials 1.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NOC icon
26
Northrop Grumman
NOC
$81.2B
$1.11M 0.72%
2,165
– –
AGI icon
27
Alamos Gold
AGI
$13.9B
$1.1M 0.71%
41,000
– –
WPM icon
28
Wheaton Precious Metals
WPM
$60.9B
$970K 0.63%
12,500
– –
DEO icon
29
Diageo
DEO
$53.6B
$707K 0.46%
6,750
– –
MREO
30
Mereo BioPharma
MREO
$47.3M
$586K 0.38%
260,470
– –
CDE icon
31
Coeur Mining
CDE
$17.9B
$569K 0.37%
+96,132
New +$593K
HOOK
32
DELISTED
HOOKIPA Pharma
HOOK
$539K 0.35%
498,625
– –
NEWP
33
New Pacific Metals
NEWP
$1.17B
$536K 0.35%
485,000
– –
VRNA
34
DELISTED
Verona Pharma
VRNA
$448K 0.29%
7,049
-192,951
-96% -$11.5M
CRDL
35
Cardiol Therapeutics
CRDL
$164M
$96.9K 0.06%
100,000
– –
GRAL
36
GRAIL Inc
GRAL
$3.1B
– –
-100
Closed -$1.78K
IRD
37
Opus Genetics
IRD
$302M
– –
-45
Closed -$53
SILV
38
DELISTED
SilverCrest Metals Inc. Common Shares
SILV
– –
-60,000
Closed -$546K
1
2

Similar funds

FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return
V
ViaWealth Leawood, Kansas $180M AUM 20.16% 1-Year Est. Return
RVM
Robinson Value Management San Antonio, Texas $180M AUM 24.17% 1-Year Est. Return

Knoll Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Knoll Capital Management held 39 positions worth $154M, down 1% from $155M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Knoll Capital Management's Q1 2025 filing shows 4 new, 2 increased, 1 reduced and 3 closed positions. Its largest new stake was Elicio Therapeutics: 630,915 shares worth $3.89M. The largest sale was Verona Pharma, an estimated $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 72% a quarter earlier, followed by Materials and Industrials.

  • Knoll Capital Management's largest Q1 2025 buy was Elicio Therapeutics: 630,915 shares worth $3.89M.
  • Knoll Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2025, an estimated $1.69M increase.
  • Knoll Capital Management's biggest Q1 2025 reduction was Verona Pharma, cutting an estimated $11.5M.
  • Knoll Capital Management fully exited SilverCrest Metals Inc. Common Shares in Q1 2025, selling an estimated $546K.
  • Knoll Capital Management's ten largest holdings make up 69% of its $154M portfolio in Q1 2025.
  • Knoll Capital Management opened 4 new positions and closed 3 in Q1 2025.
  • Knoll Capital Management's portfolio value fell 1% quarter-over-quarter to $154M.

Based on Knoll Capital Management's 13F filing for Q1 2025, filed 15 May 2025.